224 related articles for article (PubMed ID: 36409838)
1. The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain.
Bowman-Kirigin JA; Desai R; Saunders BT; Wang AZ; Schaettler MO; Liu CJ; Livingstone AJ; Kobayashi DK; Durai V; Kretzer NM; Zipfel GJ; Leuthardt EC; Osbun JW; Chicoine MR; Kim AH; Murphy KM; Johanns TM; Zinselmeyer BH; Dunn GP
Cancer Immunol Res; 2023 Jan; 11(1):20-37. PubMed ID: 36409838
[TBL] [Abstract][Full Text] [Related]
2. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
3. cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.
Ferris ST; Ohara RA; Ou F; Wu R; Huang X; Kim S; Chen J; Liu TT; Schreiber RD; Murphy TL; Murphy KM
Cancer Immunol Res; 2022 Aug; 10(8):920-931. PubMed ID: 35648641
[TBL] [Abstract][Full Text] [Related]
4. T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A
Koster BD; López González M; van den Hout MF; Turksma AW; Sluijter BJ; Molenkamp BG; van Leeuwen PA; Vosslamber S; Scheper RJ; van den Eertwegh AJ; van den Tol MP; Jordanova EJ; de Gruijl TD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737341
[TBL] [Abstract][Full Text] [Related]
5. Transcription factor Etv6 regulates functional differentiation of cross-presenting classical dendritic cells.
Lau CM; Tiniakou I; Perez OA; Kirkling ME; Yap GS; Hock H; Reizis B
J Exp Med; 2018 Sep; 215(9):2265-2278. PubMed ID: 30087163
[TBL] [Abstract][Full Text] [Related]
6. Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration.
He F; Wu Z; Liu C; Zhu Y; Zhou Y; Tian E; Rosin-Arbesfeld R; Yang D; Wang MW; Zhu D
Signal Transduct Target Ther; 2024 May; 9(1):139. PubMed ID: 38811552
[TBL] [Abstract][Full Text] [Related]
7. cDC1 prime and are licensed by CD4
Ferris ST; Durai V; Wu R; Theisen DJ; Ward JP; Bern MD; Davidson JT; Bagadia P; Liu T; Briseño CG; Li L; Gillanders WE; Wu GF; Yokoyama WM; Murphy TL; Schreiber RD; Murphy KM
Nature; 2020 Aug; 584(7822):624-629. PubMed ID: 32788723
[TBL] [Abstract][Full Text] [Related]
8. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
9. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
[TBL] [Abstract][Full Text] [Related]
10. Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
[TBL] [Abstract][Full Text] [Related]
11. Lung cDC1 and cDC2 dendritic cells priming naive CD8
Si Y; Wang Y; Tian Q; Wang Q; Pollard JM; Srivastava PK; Esser-Kahn AP; Collier JH; Sperling AI; Chong AS
Cell Rep; 2023 Oct; 42(10):113299. PubMed ID: 37864794
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
[TBL] [Abstract][Full Text] [Related]
13. Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8
Rotman J; Heeren AM; Gassama AA; Lougheed SM; Pocorni N; Stam AGM; Bleeker MCG; Zijlmans HJMAA; Mom CH; Kenter GG; Jordanova ES; de Gruijl TD
Clin Cancer Res; 2020 Jul; 26(14):3791-3802. PubMed ID: 32220890
[TBL] [Abstract][Full Text] [Related]
14. A distinct stimulatory cDC1 subpopulation amplifies CD8
Meiser P; Knolle MA; Hirschberger A; de Almeida GP; Bayerl F; Lacher S; Pedde AM; Flommersfeld S; Hönninger J; Stark L; Stögbauer F; Anton M; Wirth M; Wohlleber D; Steiger K; Buchholz VR; Wollenberg B; Zielinski CE; Braren R; Rueckert D; Knolle PA; Kaissis G; Böttcher JP
Cancer Cell; 2023 Aug; 41(8):1498-1515.e10. PubMed ID: 37451271
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of CD40-dependent cDC1 licensing beyond costimulation.
Wu R; Ohara RA; Jo S; Liu TT; Ferris ST; Ou F; Kim S; Theisen DJ; Anderson DA; Wong BW; Gershon T; Schreiber RD; Murphy TL; Murphy KM
Nat Immunol; 2022 Nov; 23(11):1536-1550. PubMed ID: 36271147
[TBL] [Abstract][Full Text] [Related]
16. Conventional Type 1 Dendritic Cells in Intestinal Immune Homeostasis.
Sasaki I; Kato T; Hemmi H; Fukuda-Ohta Y; Wakaki-Nishiyama N; Yamamoto A; Kaisho T
Front Immunol; 2022; 13():857954. PubMed ID: 35693801
[TBL] [Abstract][Full Text] [Related]
17. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1
Schenkel JM; Herbst RH; Canner D; Li A; Hillman M; Shanahan SL; Gibbons G; Smith OC; Kim JY; Westcott P; Hwang WL; Freed-Pastor WA; Eng G; Cuoco MS; Rogers P; Park JK; Burger ML; Rozenblatt-Rosen O; Cong L; Pauken KE; Regev A; Jacks T
Immunity; 2021 Oct; 54(10):2338-2353.e6. PubMed ID: 34534439
[TBL] [Abstract][Full Text] [Related]
18. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
19. Cellular cytotoxicity is a form of immunogenic cell death.
Minute L; Teijeira A; Sanchez-Paulete AR; Ochoa MC; Alvarez M; Otano I; Etxeberrria I; Bolaños E; Azpilikueta A; Garasa S; Casares N; Perez Gracia JL; Rodriguez-Ruiz ME; Berraondo P; Melero I
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217765
[TBL] [Abstract][Full Text] [Related]
20. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
